for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Transgene SA

TRNG.PA

Latest Trade

1.92EUR

Change

-0.03(-1.44%)

Volume

88,483

Today's Range

1.87

 - 

1.96

52 Week Range

1.65

 - 

3.30

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
1.95
Open
1.96
Volume
88,483
3M AVG Volume
1.50
Today's High
1.96
Today's Low
1.87
52 Week High
3.30
52 Week Low
1.65
Shares Out (MIL)
83.37
Market Cap (MIL)
162.20
Forward P/E
-6.52
Dividend (Yield %)
--

Latest Developments

More

Transgene H1 Operating Revenues Amounted To 4.9 Million Euros

Transgene Receives Approval From ANSM To Initiate Two Clinical Trials

Transgene Updates On Phocus Study Of Pexa-Vec In Liver Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Transgene SA

Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The Company also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The Company's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The Company's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

Industry

Biotechnology & Drugs

Contact Info

400 Boulevard Gonthier d'Andernach

Parc d'Innovation - CS80166

+33.3.88279100

https://www.transgene.fr

Executive Leadership

Philippe Archinard

Chairman of the Board, Chief Executive Officer, Member of the Management Committee

Christophe Ancel

Vice President - Responsible Pharmacist, Quality and Deputy CEO, Member of the Management Committee

Jean-Philippe Del

Vice President - Finance, Member of the Management Committee

Eric Quemeneur

Executive Vice President, Director of Research & Development, Member of the Management Committee

Thibaut du Fayet

Vice President Strategic Alliance, Project Management and Marketing, Member of the Management Committee

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.439

2017

-0.507

2018

0.127

2019(E)

-0.299
Price To Earnings (TTM)
15.50
Price To Sales (TTM)
22.90
Price To Book (MRQ)
3.39
Price To Cash Flow (TTM)
16.62
Total Debt To Equity (MRQ)
100.75
LT Debt To Equity (MRQ)
75.38
Return on Investment (TTM)
9.28
Return on Equity (TTM)
7.67

Latest News

AstraZeneca ties up with France's Transgene to develop viral immunotherapies

British drugmaker AstraZeneca Plc and French biopharmaceutical firm Transgene SA entered into an agreement on Thursday to co-develop five cancer-killing viral immunotherapies.

BRIEF-Transgene Q1 Operating Revenue Stable At 1.8 Million Euros

* TRANSGENE: €35.6 MILLION IN CASH AND CASH EQUIVALENTS AS OF MARCH 31, 2018

BRIEF-Transgene Says PCPV Most Promising Therapeutic Candidate Amongst Evaluated Poxviridae

* PCPV WAS FOUND TO BE MOST PROMISING THERAPEUTIC CANDIDATE AMONGST POXVIRIDAE EVALUATED BY TRANSGENE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene To Announce Major Clinical Results In 2018

* TRANSGENE TO ANNOUNCE MAJOR CLINICAL RESULTS IN 2018 AND ACHIEVE PROMISING PROGRESS ON ITS NEW ONCOLYTIC VIRUSES

BRIEF-Transgene Says ‍First Patient Dosed In China In Trial Of T101​

* FIRST CHRONIC HEPATITIS B PATIENT DOSED IN CHINA IN A PHASE 1 TRIAL OF T101

BRIEF-Transgene Announces ‍Dosing Of First Patient In Phase 2 Trial Of TG4010 Evaluation ​

* FIRST PATIENT DOSED IN A PHASE 2 TRIAL WITH TRANSGENE'S TG4010 + NIVOLUMAB + CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF LUNG CANCER (NSCLC)

BRIEF-Transgene Collaborates with BioInvent To Treat Solid Tumors

* BIOINVENT AND TRANSGENE COLLABORATE ON NEXT GENERATION ONCOLYTIC VIRUSES ENCODING AN ANTI-CTLA-4 ANTIBODY TO TREAT SOLID TUMORS

BRIEF-Transgene successfully raises 14.4 million euros

* TRANSGENE SUCCESSFULLY RAISES € 14.4 MILLION FROM U.S. AND EUROPEAN INVESTORS

BRIEF-Transgene launches capital increase by accelerated book-build offering

* TRANSGENE LAUNCHES A CAPITAL INCREASE BY WAY OF AN ACCELERATED BOOK-BUILD OFFERING

BRIEF-Transgene announces first patient has been treated in TG6002 trial

* FIRST PATIENT TREATED IN A PHASE 1/2A TRIAL (ONCOVIRAC) OF NOVEL ONCOLYTIC VIRUS TG6002 IN RECURRENT GLIOBLASTOMA

BRIEF-Transgene's TG1050 well tolerated and induces strong specific immune response

* TG1050 IS WELL TOLERATED AND INDUCES A STRONG SPECIFIC IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene Q3 operating revenue drops to 1.4 million euros

* Q3 OPERATING REVENUE EUR 1.4 MILLION VERSUS EUR 1.5 MILLION YEAR AGO

BRIEF-Transgene presents clinical data on TG1050 regarding chronic hepatitis B​

* TRANSGENE PRESENTS FIRST CLINICAL DATA INDICATING THAT TG1050 INDUCES A ROBUST AND HBV-SPECIFIC CELL-MEDIATED IMMUNE RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene peer reviewed TG4010’s ability to induce broad CD8+ responses

* PEER REVIEWED SCIENTIFIC PUBLICATIONS HIGHLIGHT TG4010’S ABILITY TO INDUCE BROAD CD8+ RESPONSES AND ITS SYNERGISTIC EFFECTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene and Randox sign collaboration to develop oncolytic virotherapies

* TRANSGENE AND RANDOX SIGN COLLABORATION TO DEVELOP INNOVATIVE MULTIFUNCTIONAL ONCOLYTIC VIROTHERAPIES FOR SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene H1 operating loss widens at 16.1 million euros

* TRANSGENE: FIRST HALF-YEAR 2017 IN LINE WITH OUR OBJECTIVES: ALL CLINICAL PROGRAMS PROGRESSING AND NEW COLLABORATION AGREEMENTS SIGNED

BRIEF-Transgene receives FDA approval to begin clinical trials in first-line treatment of lung cancer

* RECEIVES FDA IND APPROVAL TO BEGIN CLINICAL TRIAL WITH TG4010 + NIVOLUMAB + CHEMOTHERAPY IN THE FIRST-LINE TREATMENT OF LUNG CANCER

BRIEF-Transgene presents results of phase 1 part of METROmaJX trial

* PHASE 1 TRIAL RESULTS SHOWED THAT REGIMEN ASSOCIATING INTRAVENOUS INFUSION OF PEXA-VEC (JX-594) WITH LOW-DOSE CYCLOPHOSPHAMIDE WAS WELL-TOLERATED WITH NO DOSE LIMITING TOXICITY IN PATIENTS WITH SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Transgene announces cancer research publication confirming potential of its next generation armed engineered oncolytic virus

* TRANSGENE ANNOUNCES CANCER RESEARCH PUBLICATION CONFIRMING THE POTENTIAL OF ITS NEXT GENERATION ARMED ENGINEERED ONCOLYTIC VIRUS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Servier and Transgene become partners in the matter of viral vectorization technology

* SERVIER AND TRANSGENE HAVE BECOME PARTNERS TO APPLY VIRAL VECTORIZATION TECHNOLOGY TO THE ENGINEERING OF ALLOGENIC CAR-T Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up